Estimation of SARS-CoV-2 mortality during the early stages of an epidemic: A modeling study in Hubei, China, and six regions in Europe.

<h4>Background</h4>As of 16 May 2020, more than 4.5 million cases and more than 300,000 deaths from disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been reported. Reliable estimates of mortality from SARS-CoV-2 infection are essential for understanding...

Full description

Bibliographic Details
Main Authors: Anthony Hauser, Michel J Counotte, Charles C Margossian, Garyfallos Konstantinoudis, Nicola Low, Christian L Althaus, Julien Riou
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-07-01
Series:PLoS Medicine
Online Access:https://doi.org/10.1371/journal.pmed.1003189
id doaj-a3f3907166c64b31bf91c4a0bc03c091
record_format Article
spelling doaj-a3f3907166c64b31bf91c4a0bc03c0912021-04-21T18:35:48ZengPublic Library of Science (PLoS)PLoS Medicine1549-12771549-16762020-07-01177e100318910.1371/journal.pmed.1003189Estimation of SARS-CoV-2 mortality during the early stages of an epidemic: A modeling study in Hubei, China, and six regions in Europe.Anthony HauserMichel J CounotteCharles C MargossianGaryfallos KonstantinoudisNicola LowChristian L AlthausJulien Riou<h4>Background</h4>As of 16 May 2020, more than 4.5 million cases and more than 300,000 deaths from disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been reported. Reliable estimates of mortality from SARS-CoV-2 infection are essential for understanding clinical prognosis, planning healthcare capacity, and epidemic forecasting. The case-fatality ratio (CFR), calculated from total numbers of reported cases and reported deaths, is the most commonly reported metric, but it can be a misleading measure of overall mortality. The objectives of this study were to (1) simulate the transmission dynamics of SARS-CoV-2 using publicly available surveillance data and (2) infer estimates of SARS-CoV-2 mortality adjusted for biases and examine the CFR, the symptomatic case-fatality ratio (sCFR), and the infection-fatality ratio (IFR) in different geographic locations.<h4>Method and findings</h4>We developed an age-stratified susceptible-exposed-infected-removed (SEIR) compartmental model describing the dynamics of transmission and mortality during the SARS-CoV-2 epidemic. Our model accounts for two biases: preferential ascertainment of severe cases and right-censoring of mortality. We fitted the transmission model to surveillance data from Hubei Province, China, and applied the same model to six regions in Europe: Austria, Bavaria (Germany), Baden-Württemberg (Germany), Lombardy (Italy), Spain, and Switzerland. In Hubei, the baseline estimates were as follows: CFR 2.4% (95% credible interval [CrI] 2.1%-2.8%), sCFR 3.7% (3.2%-4.2%), and IFR 2.9% (2.4%-3.5%). Estimated measures of mortality changed over time. Across the six locations in Europe, estimates of CFR varied widely. Estimates of sCFR and IFR, adjusted for bias, were more similar to each other but still showed some degree of heterogeneity. Estimates of IFR ranged from 0.5% (95% CrI 0.4%-0.6%) in Switzerland to 1.4% (1.1%-1.6%) in Lombardy, Italy. In all locations, mortality increased with age. Among individuals 80 years or older, estimates of the IFR suggest that the proportion of all those infected with SARS-CoV-2 who will die ranges from 20% (95% CrI 16%-26%) in Switzerland to 34% (95% CrI 28%-40%) in Spain. A limitation of the model is that count data by date of onset are required, and these are not available in all countries.<h4>Conclusions</h4>We propose a comprehensive solution to the estimation of SARS-Cov-2 mortality from surveillance data during outbreaks. The CFR is not a good predictor of overall mortality from SARS-CoV-2 and should not be used for evaluation of policy or comparison across settings. Geographic differences in IFR suggest that a single IFR should not be applied to all settings to estimate the total size of the SARS-CoV-2 epidemic in different countries. The sCFR and IFR, adjusted for right-censoring and preferential ascertainment of severe cases, are measures that can be used to improve and monitor clinical and public health strategies to reduce the deaths from SARS-CoV-2 infection.https://doi.org/10.1371/journal.pmed.1003189
collection DOAJ
language English
format Article
sources DOAJ
author Anthony Hauser
Michel J Counotte
Charles C Margossian
Garyfallos Konstantinoudis
Nicola Low
Christian L Althaus
Julien Riou
spellingShingle Anthony Hauser
Michel J Counotte
Charles C Margossian
Garyfallos Konstantinoudis
Nicola Low
Christian L Althaus
Julien Riou
Estimation of SARS-CoV-2 mortality during the early stages of an epidemic: A modeling study in Hubei, China, and six regions in Europe.
PLoS Medicine
author_facet Anthony Hauser
Michel J Counotte
Charles C Margossian
Garyfallos Konstantinoudis
Nicola Low
Christian L Althaus
Julien Riou
author_sort Anthony Hauser
title Estimation of SARS-CoV-2 mortality during the early stages of an epidemic: A modeling study in Hubei, China, and six regions in Europe.
title_short Estimation of SARS-CoV-2 mortality during the early stages of an epidemic: A modeling study in Hubei, China, and six regions in Europe.
title_full Estimation of SARS-CoV-2 mortality during the early stages of an epidemic: A modeling study in Hubei, China, and six regions in Europe.
title_fullStr Estimation of SARS-CoV-2 mortality during the early stages of an epidemic: A modeling study in Hubei, China, and six regions in Europe.
title_full_unstemmed Estimation of SARS-CoV-2 mortality during the early stages of an epidemic: A modeling study in Hubei, China, and six regions in Europe.
title_sort estimation of sars-cov-2 mortality during the early stages of an epidemic: a modeling study in hubei, china, and six regions in europe.
publisher Public Library of Science (PLoS)
series PLoS Medicine
issn 1549-1277
1549-1676
publishDate 2020-07-01
description <h4>Background</h4>As of 16 May 2020, more than 4.5 million cases and more than 300,000 deaths from disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been reported. Reliable estimates of mortality from SARS-CoV-2 infection are essential for understanding clinical prognosis, planning healthcare capacity, and epidemic forecasting. The case-fatality ratio (CFR), calculated from total numbers of reported cases and reported deaths, is the most commonly reported metric, but it can be a misleading measure of overall mortality. The objectives of this study were to (1) simulate the transmission dynamics of SARS-CoV-2 using publicly available surveillance data and (2) infer estimates of SARS-CoV-2 mortality adjusted for biases and examine the CFR, the symptomatic case-fatality ratio (sCFR), and the infection-fatality ratio (IFR) in different geographic locations.<h4>Method and findings</h4>We developed an age-stratified susceptible-exposed-infected-removed (SEIR) compartmental model describing the dynamics of transmission and mortality during the SARS-CoV-2 epidemic. Our model accounts for two biases: preferential ascertainment of severe cases and right-censoring of mortality. We fitted the transmission model to surveillance data from Hubei Province, China, and applied the same model to six regions in Europe: Austria, Bavaria (Germany), Baden-Württemberg (Germany), Lombardy (Italy), Spain, and Switzerland. In Hubei, the baseline estimates were as follows: CFR 2.4% (95% credible interval [CrI] 2.1%-2.8%), sCFR 3.7% (3.2%-4.2%), and IFR 2.9% (2.4%-3.5%). Estimated measures of mortality changed over time. Across the six locations in Europe, estimates of CFR varied widely. Estimates of sCFR and IFR, adjusted for bias, were more similar to each other but still showed some degree of heterogeneity. Estimates of IFR ranged from 0.5% (95% CrI 0.4%-0.6%) in Switzerland to 1.4% (1.1%-1.6%) in Lombardy, Italy. In all locations, mortality increased with age. Among individuals 80 years or older, estimates of the IFR suggest that the proportion of all those infected with SARS-CoV-2 who will die ranges from 20% (95% CrI 16%-26%) in Switzerland to 34% (95% CrI 28%-40%) in Spain. A limitation of the model is that count data by date of onset are required, and these are not available in all countries.<h4>Conclusions</h4>We propose a comprehensive solution to the estimation of SARS-Cov-2 mortality from surveillance data during outbreaks. The CFR is not a good predictor of overall mortality from SARS-CoV-2 and should not be used for evaluation of policy or comparison across settings. Geographic differences in IFR suggest that a single IFR should not be applied to all settings to estimate the total size of the SARS-CoV-2 epidemic in different countries. The sCFR and IFR, adjusted for right-censoring and preferential ascertainment of severe cases, are measures that can be used to improve and monitor clinical and public health strategies to reduce the deaths from SARS-CoV-2 infection.
url https://doi.org/10.1371/journal.pmed.1003189
work_keys_str_mv AT anthonyhauser estimationofsarscov2mortalityduringtheearlystagesofanepidemicamodelingstudyinhubeichinaandsixregionsineurope
AT micheljcounotte estimationofsarscov2mortalityduringtheearlystagesofanepidemicamodelingstudyinhubeichinaandsixregionsineurope
AT charlescmargossian estimationofsarscov2mortalityduringtheearlystagesofanepidemicamodelingstudyinhubeichinaandsixregionsineurope
AT garyfalloskonstantinoudis estimationofsarscov2mortalityduringtheearlystagesofanepidemicamodelingstudyinhubeichinaandsixregionsineurope
AT nicolalow estimationofsarscov2mortalityduringtheearlystagesofanepidemicamodelingstudyinhubeichinaandsixregionsineurope
AT christianlalthaus estimationofsarscov2mortalityduringtheearlystagesofanepidemicamodelingstudyinhubeichinaandsixregionsineurope
AT julienriou estimationofsarscov2mortalityduringtheearlystagesofanepidemicamodelingstudyinhubeichinaandsixregionsineurope
_version_ 1714664719850143744